Leonardi Craig L, Gordon Kenneth B
Clinical Professor of Dermatology, Saint Louis University, Central Dermatology, St Louis, Missouri.
Professor of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Semin Cutan Med Surg. 2014 Mar;33(2 Suppl 2):S37-41. doi: 10.12788/j.sder.0066.
This article discusses the scientific rationale for the use of cytokine inhibitors, including ustekinumab, an inhibitor of the interleukin (IL)-12 and IL-23 pathways in psoriasis. Also addressed are the efficacy and safety data for this agent, as well as for several emerging therapies that target other cytokine pathways in psoriasis: the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab, the IL-23 blocker tildrakizumab, and the small-molecule kinase inhibitors apremilast (a phosphodiesterase-4 blocker) and tofacitinib (a Janus kinase inhibitor).
本文讨论了使用细胞因子抑制剂的科学依据，包括用于治疗银屑病的乌司奴单抗，它是白细胞介素（IL）-12和IL-23通路的抑制剂。还讨论了该药物以及几种针对银屑病其他细胞因子通路的新兴疗法的疗效和安全性数据：IL-17抑制剂司库奇尤单抗、依奇珠单抗和布罗达单抗，IL-23阻滞剂替拉珠单抗，以及小分子激酶抑制剂阿普斯特（一种磷酸二酯酶-4阻滞剂）和托法替布（一种Janus激酶抑制剂）。
